When COVID-19 Impacts Your Deal: Evolving M&A Practices and Provisions
March 24, 2020
From the front lines, our panelists will analyze developing best practices in addressing and allocating risk from COVID -19 as well as future outbreaks and other natural disasters, topics to include:
- Diligence – how do you diligence the impact of COVID-19 and future outbreaks on an individual target? And how do you address the reality that certain types of due diligence may not be able to be completed (management meetings, factory tours, surveys, etc.) in the current environment.
- Drafting – how agreements are being modified to address the current outbreak and future outbreaks (MAE, reps, covenants, closing conditions, financing concerns).
- Interpreting – for deals that are in the interim period now – what existing language in pending deals can be used to address COVID-19 concerns?
- Implementing the deal – we will discuss the practical considerations of getting a deal done now – RWI, HSR (including lessons learned from the government shutdown last year)
- Wilson Chu (moderator), McDermott Will & Emery, Dallas, TX
- Michael O’Bryan, Morrison Foerster, San Francisco, CA
- Jenny Hochenberg, Cravath, Swaine & Moore LLP, New York, NY
- Rita-Anne O'Neill, Sullivan & Cromwell LLP, Los Angeles, CA
- William Monat, Willis Towers Watson, Chicago, IL
Presented by: Mergers and Acquisitions Committee
Members of the Business Law Section may access the audio, program materials, and video from this program. Log in using your email address.